GlobeNewswire by notified

Obol Labs Raises $12.5M Series A Funding to Make Proof-of-Stake Blockchains More Secure

Share

Latest funding, led by Pantera Capital and Archetype, accelerates the deployment of Distributed Validator Technology, a core technology on the Ethereum scaling roadmap that improves resiliency and decentralization

NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Today, Obol Labs announced the close of a $12.5 million Series A financing round. Pantera Capital and Archetype co-led the round, with new participation from BlockTower, Nascent, Placeholder, Spartan, and IEX, and follow-on investment from Coinbase Ventures and Ethereal Ventures. This latest round brings Obol Labs' total financing to $19M, making it the best-capitalized software team focused on developing Distributed Validator Technology to decentralize and secure blockchain staking.

In September, Ethereum upgraded to Proof-of-Stake, a consensus mechanism that laid the foundation for more democratized network participation by allowing individuals with 32 ETH to run a node and validate the network. However, technical expertise is still needed to operate a node while avoiding offline and slashing penalties. For many that don't have the necessary expertise to maintain a node or want to stake in smaller quantities, exchanges and staking-as-a-service providers have filled a major market gap, now representing ~75% of the estimated $20B staked on Ethereum. While providing an important service, centralized management of stake creates a risk to the integrity of the entire network. For Ethereum to be a global settlement layer, its middleware also must be incorruptible and credibly neutral.

Obol Labs, as the leading builder of Distributed Validator Technology (DVT), is directly solving the issue of single points of failure in staking infrastructure. DVT is a technology primitive that allows an Ethereum Proof-of-Stake validator to be run simultaneously on more than one machine (mentioned in Vitalik Buterin's Ethereum roadmap). The major breakthrough is the ability to split up a single validator private key, making it possible for a group of people to share validation rights of an Ethereum validator. The company's raise in the depth of crypto winter, as venture funding has decreased by over 60%, validates the importance of DVT for the next generation of Web3 scalability.

Running a validator as a cluster of nodes means more staking resilience: validators are less likely to go offline; validator keys are less likely to be compromised; and there is less correlation risk for the entire network if validator clients have software bugs. Ultimately, DVT allows network validators of any magnitude to increase resilience, distribution of stake, and security.

Collin Myers, Obol Labs CEO and Co-Founder: "Turbulent events of 2022, including the FTX collapse, make decentralization a key priority on all levels of the Web3 stack. To make networks more secure, staking must be decentralized by design. Obol's DVT brings decentralization and resiliency to the ground floor of staking products. Our current focus is Ethereum, but in the future, we'll have implementations with Cosmos and Ethereum L2 networks."

"Obol Labs have excelled in bringing together a community of solo stakers and staking-as-a-service providers alike to advance Distributed Validator Technology. Obol plays a critical role in improving validator participation and scaling Ethereum through its next phase of growth. We are also excited to see how Obol advances DVT among other Proof-of-Stake blockchains in the coming year," said Paul Veradittakit, General Partner of Pantera Capital.

Oisín Kyne, CTO at Obol Labs, added, "Today, we think of validators as individuals or single entities. We think validators should actually be run as groups. Instead of only being able to run a validator alone, we want to enable you to run validators with a community of other stakers cooperatively."

Obol Labs is actively working with leading liquid staking protocols like Lido, Stakewise, and more to implement DVT into their operator set. In addition, a large majority of Obol's earliest seed supporters are the likes of Coinbase Ventures, Figment, Blockdaemon, Chorus One, and a collection of other industry-leading validators that are actively testing, adopting, and helping build Obol's DVT technology.

"Today, staking-as-a-service protocols and providers make up the most adopted segment of the staking industry, which makes it the most critical segment to advance infrastructures that improve staking resiliency and decentralization," said Ash Egan, Founder and General Partner of Archetype. 

In addition to working with larger validators, Obol Labs is helping to improve solo validator participation with their active community of 9,000+ members across 20+ countries. Together, at-home validators participating in Obol Labs testnets are running hundreds of multi-continent distributed validators on the Ethereum Goerli network with other operators using the recently launched DV Launchpad.

Obol Labs' Series A will accelerate the Obol Network's roadmap for bringing DVT to Mainnet Ethereum. Obol will also support the advancement of DVT across other Layer 1 Proof-of-Stake blockchains like Cosmos, as well as the L2 ecosystem to help address the resiliency of sequencers. 

About Obol Labs:

Obol Labs is an R&D team building infrastructure technologies for Ethereum and other Proof-of-Stake blockchains to scale consensus and ensure decentralization. Consisting of members across 13+ countries, the core team is currently focused on bringing Distributed Validator Technology to Ethereum. Follow at obol.tech or @ObolNetwork.

Additional Resources:

Contact Information:
Brett Li
Growth Lead
brett@obol.tech
(510) 364-9038

Related Images



To view this piece of content from cdn.newswire.com, please give your consent at the top of this page.


Image 1: Obol Logo


Official Obol Logo



This content was issued through the press release distribution service at Newswire.com.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors23.4.2024 19:42:34 CEST | Press release

Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare cancer that is often unresectable and commonly diagnosed in the late stages of disease Novartis, a leader in radioligand therapy (RLT), is investigating a portfolio of RLTs to treat a broad range of cancers, including GEP-NETs, lung, prostate, breast, colon, brain and pancreatic cancers Basel, April 23, 2024 – Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Lutathera® (USAN: lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for the treatment of pediatric patients 12 years and older with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut NETs. This approval makes Lutathera the first therapy specifically reviewed and appro

Grant of warrants23.4.2024 19:20:21 CEST | Press release

23 April 2024 Announcement no. 9 Grant of Warrants COPENHAGEN, DENMARK and BOSTON, MA, USA, April 23, 2024 (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has resolved, in accordance with the annual general meeting’s resolution on April 27, 2023, to issue a total of 4,000,000 warrants to members of the Executive Management. Each warrant grants the holder the right to subscribe for one share in BioPorto. The exercise price is DKK 1.23 per share, corresponding to the closing price today on Nasdaq Copenhagen. The warrants are issued in accordance with section 18 a of the Articles of Association. Half of the warrants vest over a 2-year period, and the remaining half upon completion of a qualified capital raise in the Company with terms of qualification (including timing and amount of proceeds) to be defined by the Board of Directors. The warrants are otherwise subject to the Company’s incentive warrant program as included in Appendix 1 o

TrueCommerce leverer globale e-fakturerings- og CTC-løsninger til virksomheder, der har udfordringer med overholdelse23.4.2024 19:10:28 CEST | pressemeddelelse

Virksomheden er ene om at tilbyde en global løsning, der omfatter e-fakturering, CTC-løsninger og et omfattende EDI-netværk, alt sammen problemfritintegreret med B2B e-handels- og ERP-systemer KØBENHAVN, Danmark, April 23, 2024 (GLOBE NEWSWIRE) -- TrueCommerce, en global leverandør af forsyningskæde- og handelspartnerforbindelser, integration og løsninger via flere kanaler, har i dag givet meddelelse om sin globale løsning til e-fakturering og Continuous Transaction Controls (CTC), der gør det muligt for organisationer at holde trit med de konstant skiftende juridiske krav overalt i verden og understøtter elektronisk fakturering, som opfylder de gældende krav. TrueCommerce er en global markedsaktør, der understøtter både e-fakturering og CTC og giver adgang til et omfattende globalt EDI-netværk samt B2B e-handel og ERP-integration. På grund af kompleksiteten i at navigere i et landskab af stadigt skiftende landespecifikke e-faktureringskrav og deadlines, står virksomheder over for en s

Festi hf.: Financial results for Q1 202423.4.2024 19:02:17 CEST | Press release

Key findings Sale of goods amounted to ISK 32,223 million, compared to ISK 29,484 million in the previous year, an increase of 9.3% between years.Gross profit from sales of goods and services amounted to ISK 7,033 million, an increase of 806 million or 12.9% between years.Profit Margins from sales of goods and services were 21.8% and increases by 0.7 p.p. from Q1 2023 but decreases by 1.2 p.p. from Q4 2023.Salaries and other personnel expenses increase by 7.5% and full-time equivalents by 2.5%.EBITDA amounted to ISK 1,898 million compared to ISK 1,401 million in Q1 2023, increase of 35.5% between years. Profit for the quarter amounted to ISK 202 million, or 2.9% of margin, a turnaround of ISK 293 million YoY.Net cash from operating activities was ISK 538 million or 7.6% of margin, compared to ISK 1,238 million last year.Equity at the end of Q1 2024 amounted to ISK 35,140 million with an equity ratio of 36.0%. EBITDA forecast for the year 2024 is raised by ISK 300 million and is now ISK

ASM reports first quarter 202423.4.2024 18:00:00 CEST | Press release

Almere, The Netherlands April 23, 2024, 6 p.m. CET Solid start of the year, Q1 orders supported by GAA and HBM ASM International N.V. (Euronext Amsterdam: ASM) today reports its Q1 2024 results (unaudited). Financial highlights € millionQ1 2023Q4 2023Q1 2024 New orders 647.4 677.5 697.9 yoy change % at constant currencies (6%) (14%) 10% Revenue 710.0 632.9 639.0 yoy change % at constant currencies 40% (7%) (8%) Gross profit margin % 49.4 % 47.2 % 52.9 % Adjusted gross profit margin 1 51.1 % 47.9 % 52.9 % Operating result 204.2 131.5 187.1 Operating result margin % 28.8 % 20.8 % 29.3 % Adjusted operating result 1 221.2 141.0 191.8 Adjusted operating result margin 1 31.2 % 22.3 % 30.0 % Net earnings 380.4 90.9 173.1 Adjusted net earnings 1 183.0 100.3 178.9 1 Adjusted figures are non-IFRS performance measures (previously referred to as "normalized"). Refer to Annex 3 for a reconciliation of non-IFRS performance measures. New orders of €698 million in Q1 2024 increased by 10% at constant

HiddenA line styled icon from Orion Icon Library.Eye